EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Selenium Supplementation Trials for Cancer Prevention and the Subsequent Risk of Type 2 Diabetes Mellitus:

Hiroshi Koyama, Mutakin, Rizky Abdulah, Chiho Yamazaki, Satomi Kameo

Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene) · 2013 · 68 (1) · 1-10

DOI: 10.1265/jjh.68.1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene), 2013. Verfasst von Hiroshi Koyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gunma University Graduate School of Medicine, Department of Public Health. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Dietary Supplements. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The essential trace element selenium has long been considered to exhibit cancer-preventive, antidiabetic and insulin-mimetic properties. However, recent epidemiological studies have indicated that supranutritional selenium intake and high plasma selenium levels are not necessarily preventive against cancer, and are possible risk factors for developing type 2 diabetes mellitus. The results of the SELECT, Selenium and Vitamin E Cancer Prevention Trial, in which it is hypothesized that the supplementations with selenium and/or vitamin E decrease the prostate cancer incidence among healthy men in the U.S., showed that the supplementation did not prevent the development of prostate cancer and that the incidence of newly diagnosed type 2 diabetes mellitus increased among the selenium-supplemented participants. The Nutritional Prevention of Cancer (NPC) trial showed a decreased risk of prostate cancer among participants taking 200 μg of selenium daily for 7.7 years. However, the results of the NPC trial also showed an increased risk of type 2 diabetes mellitus in the participants with plasma selenium levels in the top tertile at the start of the study. Recently, the association of serum selenium with adipocytokines, such as TNF-α, VCAM-1, leptin, FABP-4, and MCP-1, has been observed. Selenoprotein P has been reported to associated with adiponectin, which suggests new roles of selenoprotein P in cellular energy metabolism, possibly leading to the increased risk of type 2 diabetes mellitus and also the development of cancer. Further studies are required to elucidate the relationship between selenium and adipocytokines and the role of selenoprotein P in the development of type 2 diabetes mellitus and cancer at high levels of selenium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicDietary SupplementsAnimalsDiabetes Mellitus, Type 2HumansMaleProstatic NeoplasmsRisk FactorsSeleniumVitamin E

Substanzen

Vitamin ESelenium

Autor:innen und Institutionen

  • Gunma University Graduate School of Medicine, Department of Public Health.

Zitieren

APA

Koyama, H., Mutakin, Abdulah, R., Yamazaki, C., & Kameo, S. (2013). Selenium Supplementation Trials for Cancer Prevention and the Subsequent Risk of Type 2 Diabetes Mellitus:. Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene), 68(1), 1-10. https://doi.org/10.1265/jjh.68.1

Vancouver

Koyama H, Mutakin, Abdulah R, Yamazaki C, Kameo S. Selenium Supplementation Trials for Cancer Prevention and the Subsequent Risk of Type 2 Diabetes Mellitus:. Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene). 2013;68(1):1-10. doi:10.1265/jjh.68.1

BibTeX
@article{Koyama2013,
  author = {Koyama, Hiroshi and Mutakin and Abdulah, Rizky and Yamazaki, Chiho and Kameo, Satomi},
  title = {Selenium Supplementation Trials for Cancer Prevention and the Subsequent Risk of Type 2 Diabetes Mellitus:},
  journal = {Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene)},
  year = {2013},
  volume = {68},
  number = {1},
  pages = {1--10},
  doi = {10.1265/jjh.68.1}
}
Kostenlos starten →